GeoVax Labs, Inc. (GOVX)

Market Cap	14.95M
Revenue (ttm)	5.59M
Net Income (ttm)	-24.50M
Shares Out	23.07M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,031,055
Open	0.5050
Previous Close	0.5022
Day's Range	0.5000 - 0.6750
52-Week Range	0.4300 - 11.1800
Beta	3.36
Analysts	Strong Buy
Price Target	12.40 (+1,813.58%)
Earnings Date	Aug 5, 2025

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vacc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX
• Website: https://www.geovax.com

Analyst Summary

According to 5 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price target is $12.4, which is an increase of 1,813.58% from the latest price.

Price Target

$12.4

(1,813.58% upside)

Analyst Consensus: Strong Buy